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Background: Prolonged intermittent renal replacement therapy (PIRRT) is a growing option to treat acute kidney
injury in critically ill patients, but absent pharmacokinetic data challenge optimal drug dosing. Inappropriate
antibiotic dosing can cause widespread bacterial resistance and decreased antibiotic utility. The purpose of this
study was to evaluate probability of target attainment (PTA) of various ciprofloxacin and levofloxacin regimens in
critically ill patients receiving PIRRT, utilizing Monte Carlo simulation (MCS).
Methods: The models incorporated published body weights and pharmacokinetic parameters (volume of distribution,
non-renal clearance, and extraction coefficients) and their associated variability and ranges. Four different PIRRT
effluent/duration combinations (4 L/h × 10 h or 5 L/h × 8 h in hemodialysis or hemofiltration, respectively) occurring at
the beginning or 14-16 h after drug administration were modeled. MCS predicted drug disposition during the first 72 h
in 5000 virtual patients for each dosing regimen. Desired pharmacodynamic targets to calculate PTA were the
24-h area under the curve/minimum inhibitory concentration (AUC24h:MIC) of ≥125 and ≥50 for Gram-negative and
Gram-positive infections, respectively. The “successful” doses were the ones with PTA of ~90 % in all PIRRT settings.
Results: No conventional, FDA-approved regimens attained ~90 % of PTA for Gram-negative infection with
Pseudomonas aeruginosa at the MIC of 1 and 2 mg/L for ciprofloxacin and levofloxacin, respectively. The successful
doses (ciprofloxacin 1200 mg loading dose, 800 mg q12h, and levofloxacin 2000 mg loading dose, 1000 mg q24h
post-PIRRT) greatly exceed the maximum FDA-approved doses. For Gram-positive infections, a levofloxacin 750 mg
loading dose and 500 mg q24h post-PIRRT successfully attained PTA ~90 % at the MIC of 1 mg/L for Streptococcus
pneumoniae.
Conclusions: Ciprofloxacin and levofloxacin cannot be recommended as empiric monotherapy for serious Gram-
negative infections in patients receiving PIRRT due to suboptimal efficacy. This MCS prediction supports rational dosing
decisions to treat infected patients receiving PIRRT and should be used until clinical pharmacokinetic trials are
conducted in this population.
Keywords: Ciprofloxacin, In silico modeling, Levofloxacin, Monte Carlo simulation, Prolonged intermittent renal
replacement therapy, Pharmacodynamics, Pharmacokinetics* Correspondence: muellerb@med.umich.edu
3Department of Clinical Pharmacy, University of Michigan College of
Pharmacy, 428 Church Street, Ann Arbor, MI 48109, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lewis et al. Renal Replacement Therapy  (2016) 2:45 Page 2 of 11Background
Prolonged intermittent renal replacement therapy (PIRRT)
is a hybrid RRT used in the critical care setting as an alter-
native to conventional RRTs like intermittent hemodialysis
(IHD) or continuous renal replacement therapy (CRRT).
The typical duration of PIRRT is 6–12 h, providing the
benefits of better patient mobility and less cost compared
to CRRT, but a longer treatment period with slower flow
rates which allows for better tolerated fluid removal than
IHD [1–6]. With these unique qualities and similar patient
outcomes compared to conventional RRT, more clinicians
are considering PIRRT as a viable treatment option for
acute kidney injury in critically ill patients [1–7]. However,
very few antibiotic pharmacokinetic studies have been
conducted in patients receiving PIRRT, prompting one
set of authors to opine that PIRRT is a rational RRT that
does not allow for rational drug dosing [8]. Indeed, vali-
dated PIRRT dosing recommendations are available for
less than 1 % of drugs [8], and there is a growing under-
standing that inappropriate empiric antibiotic dosing is
associated with poor clinical outcomes in critically ill
patients [9, 10]. More than 70 % of critically ill patients
receive antibiotics, and the primary mortality cause in
these patients is infection [11]. With emerging bacterial
resistance and lack of novel antibiotic development, cli-
nicians are more pressured than ever to ensure that they
are using appropriate antibiotic doses to maximize bac-
terial eradication while ensuring safe use. Hence, more
pharmacokinetic studies are urgently needed to ensure
rational antibiotic dosing in patients receiving PIRRT.
Clinical trials are indispensable to establish antibiotic
dosing recommendations; however, clinical trials are
often not feasible. Clinical trials are expensive, and the
FDA does not mandate drug or RRT device companies
to conduct pharmacokinetic trials in PIRRT. The oper-
ating characteristics of PIRRT (duration, convective and
diffusive modalities, and effluent flow rates) vary widely;
consequently, drug dosing may vary as well. This makes
it unlikely that sufficient PIRRT pharmacokinetic trials
will ever be conducted in these vulnerable patients. Al-
ternative approaches to clinical trials are needed to de-
velop appropriate dosing in PIRRT. For decades, in
silico trials using Monte Carlo simulation (MCS) have
been used to determine optimal drug regimens during
drug discovery and development. This approach has
been employed to predict optimal antibiotic doses in pa-
tients with IHD and CRRT [12, 13], but not with PIRRT.
Antibiotic dosing in patients with PIRRT is challenging,
because dosing must take into account the pharmaco-
kinetics altered not only by critical illness and but also
by the timing of PIRRT and its associated drug clearance
in relation to drug administration [14]. However, in
silico trials can integrate our current understanding of
PIRRT’s influence on drug disposition and can informappropriate antibiotic dosing in this patient population
with limited available pharmacokinetic data generated
from more conventional sources like clinical trials.
Ciprofloxacin and levofloxacin are fluoroquinolone anti-
biotics, often prescribed to treat moderate to severe infec-
tions in critically ill patients. They exert concentration-
dependent bactericidal activity against most Gram-negative
aerobic pathogens and some Gram-positive organisms.
However, the widespread dissemination of fluoroquinolone
resistance among key pathogens can limit their use [15, 16].
For example, fluoroquinolone resistance rates in Gram-
negative bacilli species such as Pseudomonas aeruginosa in
ICUs have more than doubled from 11 % in 1990–1993 to
27.4 % in 2011 [16, 17]. The decline of fluoroquinolone ac-
tivity may be the most concerning of all antibiotic resist-
ance patterns among Gram-negative pathogens in the ICU.
The emergence of fluoroquinolone resistance among many
Gram-positive pathogens has also reduced its clinical utility
in the ICU [18, 19]. Frequent prescribing and suboptimal
dosing contributed to this alarming trend [9, 20]. Previous
studies indicated that the 24-h area under the curve
(AUC24h):minimum inhibitory concentration (MIC) ratio is
the pharmacodynamic parameter most predictive of fluoro-
quinolone efficacy [21]. A total AUC24h:MIC ≥125 has been
correlated with optimal clinical outcomes in critically ill
patients infected with Gram-negative pathogens including
P. aeruginosa [22], while a lower target of a total AUC24h:-
MIC ≥50 is sufficient to treat Gram-positive pathogens
such as S. pneumoniae [23]. Fluoroquinolone-associated
toxicities are mild-to-moderate in most cases. However,
fluoroquinolone-associated cardiovascular toxicity (i.e., pro-
longation of QT interval) that can potentially lead to life-
threatening torsades de pointes [24, 25] is a rising concern,
especially in high-risk patient populations such as critically
ill patients who may require higher doses. Central nervous
system (CNS) adverse effects may be commonly observed
with fluoroquinolone therapy, especially in patients with a
previous CNS impairment [26]. The risk factors are likely
patient-specific, but it is suggested that dosing regimens
should not exceed the FDA-approved doses to prevent
these toxicities [25]. Currently, no ciprofloxacin pharmaco-
kinetic studies have been published in PIRRT. Levofloxacin
has been evaluated in one small study (n = 5) with extended
daily dialysis, one type of PIRRT, but the optimal dosing
has not been determined [27]. With this lack of available
pharmacokinetic dosing data, pharmacist-recommended
fluoroquinolone doses in patients receiving PIRRT vary
extensively, with up to fivefold dosing differences being
proposed [28]. The objective of the present study was to
predict the likelihood of pre-defined pharmacodynamic tar-
get attainment in intravenous ciprofloxacin and levofloxa-
cin dosing regimens as empiric treatment for serious
Gram-negative infections in virtual patients receiving daily
PIRRT using MCS techniques. Additionally, intravenous
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ment of Gram-positive infections.
Methods
Pharmacokinetic model development
The model integrated relevant input parameters to con-
struct a realistic virtual patient population, as outlined in
Table 1. Body weight was derived from a large PIRRT
study [4] and pharmacokinetic data from published cipro-
floxacin and levofloxacin pharmacokinetic studies in crit-
ically ill patients receiving RRT [29–36]. In order to avoid
spurious simulations, limits were obtained from those pre-
vious studies and were set for all input parameters. Body
weight lower limits were set at ≥40 kg assuming that the
virtual patients are adults [4]. The ranges of volume of dis-
tribution (Vd) and non-renal clearance values (CLNR) were
extracted from the relevant ciprofloxacin and levofloxacin
pharmacokinetic studies [29–36]. The correlation (i.e., co-
efficient of determination, r2) between body weight and Vd
or CLNR were also derived from those previous studies
and integrated into the models to construct realistic phar-
macokinetic parameters. The relationship between these
parameters was found to be not significant except for that
between body weight and CLNR for levofloxacin [33].
Transmembrane RRT drug clearance was calculated by
multiplying effluent flow rate (dialysate (Qd) and/or ultra-
filtrate flow rate (Quf)) by the extraction coefficient (also
called sieving coefficient for hemofiltration and saturation
coefficient for hemodialysis) which is the percentage of
drug that crosses the hemodiafilter membrane. For siev-
ing/saturation coefficients, the upper limit was set at 1.
The model integrated four commonly employed PIRRT set-
tings, using two different effluent flow rates/durations in
hemodialysis and hemofiltration modes. They were as
follows: (1) hemofiltration mode with Quf of 4 L/h for 10 h/
day, (2) hemofiltration mode with Quf of 5 L/h for 8 h/day,
(3) hemodialysis mode with Qd of 4 L/h for 10 h/day, and
(4) hemodialysis mode with Qd of 5 L/h for 8 h/day. BloodTable 1 Input parameters used in in silico ciprofloxacin and levoflox
Demographic and pharmacokinetic parameters
Weight (kg)







Dialysate/ultrafiltration flow rate and duration
All values are represented as mean ± SD [assigned model limits]flow rate was set at 300 mL/min in all PIRRT settings. For
hemofiltration mode, all replacement fluid was modeled to
be administered using the pre-dilution mode as used com-
monly in clinical practice. The equations used in the model
were following:
CLHD L=hð Þ ¼ SA  Qd
CLHF L=hð Þ ¼ SC  Quf  Qplasma= Qplasma þ Qreplacement
  
V d Lð Þ ¼ WT  V d L=kgð Þ
kon ¼ CLNR þ CLHDð Þ=V d for hemodialysis modeð Þ
kon ¼ CLNR þ CLHFð Þ=V d for hemofiltration modeð Þ
koff ¼ CLNR=V d
[37, 38]
where CLHF is transmembrane clearance in hemofiltra-
tion; SC is sieving coefficient; Quf is ultrafiltrate flow rate;
Qplasma is plasma flow rate (Qplasma =Qblood*(1− hematocrit);
hematocrit is 30 % [38]); Qreplacement is replacement fluid
flow rate (Qreplacement =Quf); CLHD is transmembrane clear-
ance in hemodialysis; SA is saturation coefficient; Qd is di-
alysate flow rate; Vd is volume of distribution; WT (kg) is
body weight; kon is the elimination rate constant during
PIRRT; CLNR is non-renal clearance; and koff is the elimin-
ation rate constant off PIRRT.
Monte Carlo simulations
Pharmacodynamic exposures were modeled using a one-
compartment model with constant intravenous input and
first-order elimination (Additional file 1). MCS (Crystal
Ball Classroom Edition, Oracle) was performed to gener-
ate total serum concentration-time profiles, following a
previously published method [39]. Twelve different
ciprofloxacin and 17 different levofloxacin dosing regi-
mens including those recommended for patients receiving
other types of RRT and those for normal kidney function
were simulated with infusion time of 1 h for both agents
[40, 41]. Fluoroquinolone disposition was assessed for the
first 72 h in order to evaluate the relative influences ofacin dosing trials in PIRRT [30–36]
Ciprofloxacin Levofloxacin
86.6 ± 29.2 [≥40]
1.25 ± 0.4 [0.5–1.92] 1.2 ± 0.4 [0.7–2.08]
116 ± 61 [13–259] 25.7 ± 14 [0.12–67]




4 L/h for 10 h or 5 L/h for 8 h
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ing intervals (e.g., 48 h). In clinical practice, fluoroquino-
lone doses can be administered at the beginning of, or
during the middle of PIRRT, or several hours prior to a
PIRRT session. In order to consider all clinical situations,
we simulated each fluoroquinolone dosing regimen in the
two most extreme scenarios in each of four PIRRT set-
tings. One scenario was when the PIRRT is commenced at
the beginning of first fluoroquinolone dose infusion (early
PIRRT), and the other scenario was when PIRRT occurred
14 or 16 h after the first fluoroquinolone dose is adminis-
tered (late PIRRT).
Probability of target attainment prediction
The pharmacodynamic targets used in these in silico tri-
als were AUC24h:MIC ≥125 for each 24 h period during
the initial 72 h therapy for Gram-negative infections and
AUC24h:MIC ≥50 for Gram-positive infections [23, 24].
AUC24h was calculated by 24-h area under the curve
using the linear trapezoidal formula. The reference
Gram-negative pathogen was P. aeruginosa which is as-
sociated with the increased mortality rates in the ICUs
[42]. Based on the Clinical and Laboratory Standards In-
stitute, the clinical breakpoint of P. aeruginosa is 1 mg/L
for ciprofloxacin and 2 mg/L for levofloxacin [43]. For
Gram-positive infection simulations, S. pneumoniae was
chosen and its clinical breakpoint for levofloxacin is
2 mg/L [43]. Probability of target attainment (PTA) was
calculated by summing up the virtual patient numbers
achieving the pre-defined pharmacodynamic target and
dividing by the total number of patients (n = 5000). In
addition, PTA of each dosing regimen was calculated at
doubling MIC dilutions ranging from 0.25 to 4 mg/L. If
a regimen yielded ~90 % of PTA in all PIRRT settings re-
gardless of the time of PIRRT institution in relation to
the first drug administration using the smallest daily
dose, the dosing regimen was considered “successful.”
However, benefits of achieving the pharmacodynamic target
had to be weighed against the risk of drug toxicity. No pub-
lished studies are available to clearly define fluoroquinolone
exposure and a toxicity concentration threshold. Given that
these patients with PIRRT are more vulnerable to experi-
ence fluoroquinolone-associated cardiovascular and CNS
toxicities that can be life-threatening, we decided a priori
that any dosing recommendation would not exceed within
the FDA-approved intravenous doses (1200 mg/day for cip-
rofloxacin and 750 mg/day for levofloxacin) due to safety
concerns [25, 40, 41].
Sensitivity analyses
Sensitivity analyses were performed to investigate the influ-
ence of different PIRRT operational settings on fluoroquino-
lone clearance by PIRRT. As mentioned, fluoroquinolone
dosing regimens in early vs. late PIRRT were compared toassess whether “when” to give a drug in relation to PIRRT
substantially impacted PTA. Many other RRT-specific fac-
tors can affect extracorporeal drug clearance. However,
where blood flow rate is much higher than effluent flow rate
(like the PIRRT settings in our model), the effluent flow rate
is the most important covariate to determine extracorporeal
drug clearance in RRT [44]. Consequently, we re-evaluated
PTA of the successful fluoroquinolone dosing regimens
from this present study in a wide array of effluent flow rates
ranging from 2 to 10 L/h using the same treatment dur-
ation. Sensitivity analyses were performed for all successful
ciprofloxacin and levofloxacin doses for serious Gram-
negative infection in 8- and 10-h hemofiltration treatments.
Sensitivity analyses could not be performed in hemodialysis
experiments because of limited published extraction coeffi-
cient data in hemodialysis at varying dialysate flow rates.
Results
Tables 2 and 3 summarize the PTA results of selected
ciprofloxacin and levofloxacin dosing regimens to treat
Gram-negative infections with P. aeruginosa and Gram-
positive infections with S. pneumoniae, respectively, dur-
ing the initial 72 h of therapy in both early and late
PIRRT settings. The PTA difference in early or late
PIRRT only ranged 1–2 % among the four different RRT
settings in simulation results. Thus, the results of the 8-
h hemodialysis PIRRT were presented as representative
examples of the other RRT settings. None of the clinic-
ally used ciprofloxacin and levofloxacin dosing regimens,
including the FDA-approved maximum doses for pa-
tients with normal renal function, attained ~90 % of
PTA as treatment of Gram-negative infection with P.
aeruginosa. The approved maximal doses of intravenous
ciprofloxacin for patients with normal renal function
(400 mg q8h) attained PTAs of only ~30, 70–71, and
76 % on days 1, 2, and 3, respectively. For levofloxacin,
750 mg q24h yielded only ~10, 25–44, and 46–64 % on
days 1, 2, and 3, respectively. The simulation results pre-
dicted that ciprofloxacin regimen of 1200 mg loading
dose (LD), then 800 mg q12h, and levofloxacin regimen
of 2000 mg loading dose, then 1000 mg q24h post-
PIRRT, would be required to attain PTA of ~90 % or
greater to treat Gram-negative infections with P. aerugi-
nosa regardless of the time of daily PIRRT institution.
For Gram-positive infections, however, the levofloxacin
regimen of 750 mg LD, then 500 mg q24h post-PIRRT,
successfully met ~90 % PTA. Substantial differences of
PTA in early vs. late PIRRT were only observed in levo-
floxacin trials, likely because of its longer (q24h-q48h)
dosing intervals (Tables 2 and 3). Figure 1 illustrates the
PTA at AUC24h:MIC ≥125 for selective ciprofloxacin
and levofloxacin dosing regimens at specific MICs in
early and late PIRRT to treat Gram-negative infections.
Figure 2 depicts the PTA at AUC24h:MIC ≥50 for
Table 2 Probability of target attainment of selected ciprofloxacin and levofloxacin dosing regimens for Gram-negative infection with
P. aeruginosaa in 5000 virtual patients with 8-h hemodialysis PIRRT at dialysate flow rate of 5 L/h during the initial 72 h


















200 mg q12h 0.0 0.0 0.0 0.0 0.0 0.3 0.6 0.1
400 mg q12h 3.9 24.3 33.4 17.3 7.8 30.0 38.0 23.8
800 mg q12h 66.6 91.2 92.5 87.9 72.5 92.6 93.7 90.1
200 mg q8h 0.3 5.8 11.2 3.5 0.4 5.5 10.5 3.5
400 mg q8h 27.7 71.0 76.2 62.2 30.1 70.3 75.6 63.3
600 mg q8h 75.4 96.1 96.9 93.9 76.3 96.2 96.9 94.3
1200 mg LD, then 800 mg q12h 89.9 92.3 92.7 92.9 93.1 94.2 94.4 94.8
Levofloxacin
750 mg q24h 1.7 25.4 45.9 24.4 9.9 43.5 63.5 39.0
750 mg LD, then 250 mg q24h
post-PIRRT
11.1 3.6 1.7 5.5 10.0 3.1 1.6 4.9
750 mg LD, then 500 mg q24h
post-PIRRT
27.4 32.0 35.0 31.5 10.4 20.8 28.6 20.0
750 mg LD, then 750 mg q24h
post-PIRRT
45.3 65.5 73.9 61.5 10.9 44.1 63.1 39.4
1500 mg LD, then 750 mg q24h
post-PIRRT
83.7 84.2 83.4 83.8 66.3 74.1 77.6 72.7
1500 mg LD, then
1000 mg q24h post-PIRRT
89.2 93.8 95.3 92.8 67.2 84.8 91.4 81.2
2000 mg LD, then 1000 mg q24h
post-PIRRT
96.4 97.1 96.9 96.8 87.5 92.5 94.5 91.5
Bolded dosing regimens are the ones that attained PTA of ~90 % or greater in both early and late PIRRT, using the smallest daily dose
LD loading dose
aPharmacodynamic target used for Gram-negative infection was AUC24h:MIC ≥125 with MIC = 1 mg/L for ciprofloxacin and MIC = 2 mg/L for levofloxacin (susceptibility
breakpoint for Pseudomonas aeruginosa)
bEarly PIRRT: when the first fluoroquinolone dose is administered with the commencement of a daily PIRRT session
cLate PIRRT: when the first fluoroquinolone dose is administered 16 h before a daily PIRRT session
Table 3 Probability of target attainment of selective levofloxacin dosing regimens for Gram-positive infection with S. pneumoniaea
in 5000 virtual patients with 8-h hemodialysis PIRRT at dialysate flow rate of 5 L/h during the initial 72 h


















500 mg q48h 33.2 0.0 66.0 33 50.0 0.0 76.8 43.5
500 mg q24h 32.4 82.3 93.6 69.4 49.2 87.7 96.3 77.7
750 mg LD, then 250 mg q24h
post-PIRRT
90.3 85.5 78.4 84.7 82.4 78.4 73.9 78.3
750 mg LD, then 500 mg q24h
post-PIRRT
96.2 98.3 99.0 97.8 83.6 94.6 97.7 91.9
750 mg LD, then 750 mg q24h
post-PIRRT
98.8 99.9 99.9 99.6 84.1 98.8 99.9 94.3
Bolded dosing regimens are the ones that attained PTA of ~90 % or greater in both early and late PIRRT, using the smallest daily dose
LD loading dose
aPharmacodynamic target used for Gram-positive infection was AUC24h:MIC ≥50 with MIC = 2 mg/L for levofloxacin (susceptibility breakpoint for
Streptococcus pneumoniae)
bEarly PIRRT: when the first fluoroquinolone dose is administered with the commencement of a daily PIRRT session
cLate PIRRT: when the first fluoroquinolone dose is administered 16 h before a daily PIRRT session
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Fig. 1 PTA of ciprofloxacin/levofloxacin regimens at different MICs in virtual patients with Gram-negative infection in PIRRT. Early PIRRT is when
the first intravenous ciprofloxacin or levofloxacin dose is administered with the commencement of an 8-h daily PIRRT session. Late PIRRT is when
the first intravenous fluoroquinolone dose is administered 16 h before a daily 8-h PIRRT session. The PTA results were the average of PTA on each
24 h period during the initial 72 h therapy in virtual patients with 8-h hemodialysis PIRRT with 5 L/h of dialysate flow rate
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for treatment of Gram-positive infections. The additional
information on PTA of selected ciprofloxacin and
levofloxacin dosing regimens in the other three PIRRT
settings is provided as Additional files 2 and 3. Table 4
depicts results of further sensitivity analyses with respect to
effluent flow rates. Employment of different effluent flow
rates of the same treatment duration did not yield substan-
tially different PTAs of the fluoroquinolone dosing regi-
mens from this present study in 8-h hemofiltration PIRRT.
Sensitivity analyses of the other studied flow rates are
nearly identical.
Discussion
This is the first in silico trial using MCS to evaluate vari-
ous fluoroquinolone dosing regimens to treat critically ill
patients with PIRRT. This approach permits incorporationof the commonly used PIRRT settings into the models
with existing demographic and pharmacokinetic parame-
ters published from critically ill patients receiving RRT to
predict fluoroquinolone serum concentrations in patients
receiving PIRRT. The MCS tested the PTA of various
fluoroquinolone regimens in a large virtual cohorts (n =
5000) who had the same variability in their personal phar-
macokinetic profiles as has been seen in the published
fluoroquinolone pharmacokinetic literature conducted in
critically ill patients. These in silico trials illustrate that
MCS can be highly useful and a cost-effective approach to
assess expected efficacy of various antibiotic dosing regi-
mens and to guide appropriate antibiotic dosing in this
special patient population with limited pharmacokinetic
data.
The present study predicts that even maximal recom-
mended ciprofloxacin (1200 mg/day) and levofloxacin
Fig. 2 PTA of levofloxacin regimens at different MICs in virtual patients with Gram-positive infection in PIRRT. Early PIRRT is when the first intravenous
levofloxacin dose is administered with the commencement of an 8-h daily PIRRT session. Late PIRRT is when the first intravenous levofloxacin dose is
administered 16 h before a daily 8-h PIRRT session. The PTA results were the average of PTA on each 24 h period during the initial 72 h therapy in
virtual patients with 8-h hemodialysis PIRRT with 5 L/h of dialysate flow rate
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exposure to treat Gram-negative infections with P. aeru-
ginosa (MIC of 1 mg/L for ciprofloxacin and 2 mg/L for
levofloxacin) in most critically ill patients receiving
PIRRT. The simulation results indicate that a total of
2000 mg of ciprofloxacin is required on day 1 and
1600 mg for days 2 and 3 to attain the accepted pharma-
codynamic target (AUC24h:MIC ≥125) in ~90 % or
greater of virtual patients. For levofloxacin, 2000 mg was
required for day 1 and 1000 mg on days 2 and 3. These
MCS results are not surprising, because of the growingTable 4 PTA sensitivity analyses of “successful” fluoroquinolone
dosing recommendation with various effluent flow rates in PIRRT
AUC24h:MIC
a ≥125
8-h hemofiltration in early PIRRT










PTA data were from 8-h PIRRT using a 5 L/h effluent flow rate (ultrafiltrate flow
rate) with blood flow rate of 300 mL/min. Similar PTA was resulted from
10-h PIRRT
aMIC = 1 mg/L for ciprofloxacin and MIC = 2 mg/L for levofloxacin
(susceptibility breakpoint for Pseudomonas aeruginosa)
bReference flow rate used in this studyrealization that conventional fluoroquinolone doses do
not reliably achieve the pharmacodynamic target of
AUC24h:MIC ≥125 in infected critically ill patients with or
without RRT [36, 45–49]. In a recent report, ciprofloxacin
1600 mg/day was necessary to attain AUC24h:MIC ≥125
(bacterial susceptibility of MIC ≤ 1 mg/L) at a steady state
in an obese critically ill patient receiving CRRT [49]. A
previous study with 14 critically ill patients with P. aerugi-
nosa infection receiving CRRT also reported the com-
monly recommended ciprofloxacin dose (400 mg q24h)
for CRRT [50] was inadequate to attain even a less rigor-
ous pharmacodynamic target (AUC24h:MIC ≥100) [36].
The present study shows that even the use of conventional
doses recommended for normal renal function in patients
with PIRRT would yield inadequate drug exposure. How-
ever, no clinical studies have been conducted to evaluate
the safety of fluoroquinolone doses that are higher than
recommended in critically ill patients. Consequently, it is
advised that ciprofloxacin and levofloxacin should not be
used as empiric monotherapy for serious Gram-negative
infections in patients receiving PIRRT due to concerns of
suboptimal antibiotic exposure. In situations when fluoro-
quinolones are to be used in combination with another
primary antibiotic, we would recommend the maximal
doses, at least 400 mg q8h for ciprofloxacin and 750 mg
loading dose, followed by 750 mg q24h post-PIRRT for
levofloxacin.
The higher the RRT flow rate, the higher the fluoro-
quinolone RRT clearance should be, and our findings
were consistent with previous studies. The estimated
mean fluoroquinolone clearances (55.0 mL/min for cip-
rofloxacin and 48.3 mL/min for levofloxacin with an ef-
fluent rate of 83 mL/min) by PIRRT in the present study
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ciprofloxacin and 11.0–27.6 mL/min for levofloxacin) in
CRRT that used lower effluent flows of 17–30 mL/min
(Table 5) [30–34, 36, 37]. In contrast, our calculated
PIRRT clearances were also lower than those published in
IHD with effluent flow rates of 500–600 mL/min [51, 52].
The levofloxacin clearance by PIRRT in this present study
was similar to the clearance reported in five patients with
extended daily dialysis (48.8 [25.2–72.5] mL/min as med-
ian[range]), another type of PIRRT [27]. However, levo-
floxacin half-life was shorter in this previous study (34.5
[21.2–47.7] hours as median[range] vs. 52.8 + 17.0 h) be-
cause the levofloxacin CLNR was higher than that used in
this study (51.0 [49.0–52.8] mL/min as median[range] vs.
24.7 + 11.7 mL/min) [27]. This levofloxacin CLNR in the
previous study was reported to be much higher than all of
those reported in other published studies with similar
patient population receiving CRRT (mean range of 15.0–
30.9 mL/min) (Table 5) [31–34].
Sensitivity analyses evaluated the influence of different
PIRRT operation settings on PTA of fluoroquinolone
dosing regimens. It has been suggested that for PIRRT,
“when” to administer a drug relative to PIRRT institu-
tion may be a more important factor than “how much”
drug to give [14]. Sensitivity analyses indicate that this is
the case for a drug with longer half-life that is given in-
frequently like levofloxacin. For example, PTA of levo-
floxacin q24h–q48h dosing regimens differed by up to
20 % in early vs. late PIRRT as shown in Tables 2 and 3.
However, ciprofloxacin, which is given more frequentlyTable 5 Modeled fluoroquinolone clearances and half-lives in PIRRT
Ciprofloxacin
PIRRT (present study) CRRT [30
QEffluent (mL/min) 83.3 17–50
b
CLRRT (mL/min) 55.0 ± 13.3
a 13.3–41.7
CLOFF-RRT (mL/min) 108.3 ± 48.3
a 102–166
t½ ON-RRT (h) 8.2 ± 5.0
a 9.4–13.8b
t½ OFF-RRT (h) 13.9 ± 10.5
a N/A
Levofloxacin
PIRRT (present study) CRRT [31
QEffluent (mL/min) 83.3 17–50
b
CLRRT (mL/min) 48.3 + 15.0
a 11.0–27.6
CLOFF-RRT (mL/min) 24.7 + 11.7
a 15.0–30.9
t½ ON-RRT (h) 16.7 + 6.0
a 8.3–45.9b
t½ OFF-RRT (h) 52.8 + 17.0
a N/A
Clearance and half-life data in PIRRT were from on and off 8-h hemodialysis PIRRT
N/A not applicable, N/S not studied, N/R not reported, PIRRT prolonged intermittent
extended daily dialysis, IHD intermittent hemodialysis, QEffluent effluent flow rate, CL
RRT, T½ ON-RRT half-life during RRT, T½ OFF-RRT half-life off-RRT
aMean ± SD
bMean ranges reported from the references
cMedian [range]with q8h–q12h dosing regimens yielded only 1–6 %
PTA difference in early vs. late PIRRT (Table 2). PIRRT
operating settings vary from institution to institution,
and the PIRRT variable that is most varied between insti-
tutions is effluent rate. Some centers are more aggressive
and use high effluent rates, while others use rates closer
to what is seen in CRRT. We assessed the influence of
this commonly modified parameter in Table 4. Interest-
ingly, the effluent rate had a surprisingly small influence
on PTA rates. Varying effluent rates from 2 to 10 L/h
(our models used 4 and 5 L/h) for 8–10 h only changed
PTA by 2–4 %. This 2–4 % difference caused by effluent
flow rates is dwarfed by the change in PTA caused by
“when” the dose is given in relation to PIRRT.
This study has some limitations. Simulations were per-
formed under the assumption that patients were adult-sized
with negligible renal drug clearance and were characterized
with literature-based demographic and pharmacokinetic pa-
rameters. The model also incorporated “daily” PIRRT. Thus,
our recommendation should be applied to those who match
these demographic and pharmacokinetic characteristics and
receive daily PIRRT. Any time that MCSs are used to inform
antibiotic dosing, clinical validation is warranted. However,
in this case, it would appear to be unethical to conduct a
fluoroquinolone PIRRT pharmacokinetic trial with the doses
that achieved 90 % PTA because these doses are likely to be
toxic. We have confidence that the model performed accur-
ately based on the fact that our findings independently cor-
roborate reports that conventionally dosed fluoroquinolones
rarely achieve therapeutic targets in critically ill patients, andand comparison to pharmacokinetic data in other types of RRT




N/S 3.2 ± 0.4a
N/S 5.8 ± 0.9a
–34] EDD [27] IHD [50]
160 600
b 48.8 [25.2–72.5]c 84.4 [61.8–107.6]c
b 51.0 [49.0–52.8]c 37.0 [12.8–42.7]c
10.3 [10.0–10.6]c N/R
34.5 [21.2–47.7]c 34.4 [28.4–39.3]c
renal replacement therapy, CRRT continuous renal replacement therapy, EDD
RRT drug clearance by renal replacement therapy, CLOFF-RRT drug clearance off
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their use as empiric monotherapy in this population receiv-
ing PIRRT due to the concern for suboptimal serum con-
centration attainment that contributes to increasing
bacterial resistance. Although smaller levofloxacin doses can
be used to treat S. pneumonia in PIRRT patients based on
our data, the maximal FDA-approved fluoroquinolone dose
should be used as empiric treatment for infected critically ill
patients with PIRRT as combination therapy when
necessary. Even as adjunctive therapy, fluoroquinolones are
associated with potentially life-threatening cardiovascular
and CNS toxicities [24–26]. Thus, close monitoring for car-
diovascular- and neurotoxicity should be followed when this
fluoroquinolone dosing is used to treat these vulnerable
patients.
Conclusions
In silico trials using MCS are useful and may be the only
alternative to guide appropriate antibiotic dosing where
pharmacokinetic data are absent and clinical trials are
not likely to be conducted. This simulation study indi-
cated that none of the conventional ciprofloxacin and
levofloxacin dosing regimens are likely to be efficacious
as empiric treatment for Gram-negative infections
caused by P. aeruginosa in critically ill patients with
daily PIRRT. Pharmacodynamic target attainment during
the initial 72 h required up to three to fourfold higher
fluoroquinolone doses than the maximally approved
doses in these patients. Use of these extreme dosing reg-
imens cannot be recommended because of concerns of
fluoroquinolone-associated toxicity in these vulnerable
patients. These in silico simulations support rational
dosing decision for clinicians treating infected patients
receiving PIRRT and should be used until clinical phar-
macokinetic trials are conducted in this population.
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